151 related articles for article (PubMed ID: 34895843)
41. Epidemiology and risk factors for invasive fungal infections during induction chemotherapy for newly diagnosed acute myeloid leukemia: A retrospective cohort study.
Lien MY; Chou CH; Lin CC; Bai LY; Chiu CF; Yeh SP; Ho MW
PLoS One; 2018; 13(6):e0197851. PubMed ID: 29883443
[TBL] [Abstract][Full Text] [Related]
42. Efficacy of antifungal prophylaxis with oral suspension posaconazole during induction chemotherapy of acute myeloid leukemia.
Schrenk KG; Schnetzke U; Stegemann K; von Lilienfeld-Toal M; Hochhaus A; Scholl S
J Cancer Res Clin Oncol; 2015 Sep; 141(9):1661-8. PubMed ID: 25800622
[TBL] [Abstract][Full Text] [Related]
43. Evaluation of the practice of antifungal prophylaxis use in patients with newly diagnosed acute myeloid leukemia: results from the SEIFEM 2010-B registry.
Pagano L; Caira M; Candoni A; Aversa F; Castagnola C; Caramatti C; Cattaneo C; Delia M; De Paolis MR; Di Blasi R; Di Caprio L; Fanci R; Garzia M; Martino B; Melillo L; Mitra ME; Nadali G; Nosari A; Picardi M; Potenza L; Salutari P; Trecarichi EM; Tumbarello M; Verga L; Vianelli N; Busca A;
Clin Infect Dis; 2012 Dec; 55(11):1515-21. PubMed ID: 22955439
[TBL] [Abstract][Full Text] [Related]
44. Invasive fungal infection in patients receiving chemotherapy for hematological malignancy: a multicenter, prospective, observational study in China.
Sun Y; Huang H; Chen J; Li J; Ma J; Li J; Liang Y; Wang J; Li Y; Yu K; Hu J; Jin J; Wang C; Wu D; Xiao Y; Huang X
Tumour Biol; 2015 Feb; 36(2):757-67. PubMed ID: 25293517
[TBL] [Abstract][Full Text] [Related]
45. A Prospective Observational Multi-institutional Study on Invasive Fungal Infections Following Chemotherapy for Acute Myeloid Leukemia (MISFIC Study): A Real World Scenario from India.
George B; Menon H; Bhurani D; Damodar S; Apte S; Seth T; Sharma A; Shyam R; Malhotra P; Easow J; Lakshmi KM; Agrawal N; Sengar M; Nataraj KS; Ahmed R; Sharma S; Khadwal A; Prakash G; Abraham A; Devasia A; Korula A; Mathews V
Indian J Hematol Blood Transfus; 2020 Jan; 36(1):97-103. PubMed ID: 32158091
[TBL] [Abstract][Full Text] [Related]
46. Real-life comparison of posaconazole versus fluconazole for primary antifungal prophylaxis during remission-induction chemotherapy for acute leukemia.
Dufresne SF; Bergeron J; Beauchemin S; Abou Chakra CN; Vadnais B; Bouchard P; Labbé AC; Laverdière M
J Assoc Med Microbiol Infect Dis Can; 2023 Mar; 8(1):18-28. PubMed ID: 37008582
[TBL] [Abstract][Full Text] [Related]
47. Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO).
Mellinghoff SC; Panse J; Alakel N; Behre G; Buchheidt D; Christopeit M; Hasenkamp J; Kiehl M; Koldehoff M; Krause SW; Lehners N; von Lilienfeld-Toal M; Löhnert AY; Maschmeyer G; Teschner D; Ullmann AJ; Penack O; Ruhnke M; Mayer K; Ostermann H; Wolf HH; Cornely OA
Ann Hematol; 2018 Feb; 97(2):197-207. PubMed ID: 29218389
[TBL] [Abstract][Full Text] [Related]
48. Oral voriconazole versus intravenous low dose amphotericin B for primary antifungal prophylaxis in pediatric acute leukemia induction: a prospective, randomized, clinical study.
Mandhaniya S; Swaroop C; Thulkar S; Vishnubhatla S; Kabra SK; Xess I; Bakhshi S
J Pediatr Hematol Oncol; 2011 Dec; 33(8):e333-41. PubMed ID: 22042283
[TBL] [Abstract][Full Text] [Related]
49. Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome.
Krishna G; AbuTarif M; Xuan F; Martinho M; Angulo D; Cornely OA
Pharmacotherapy; 2008 Oct; 28(10):1223-32. PubMed ID: 18823218
[TBL] [Abstract][Full Text] [Related]
50. Invasive fungal infections in pediatric leukemia patients receiving fluconazole prophylaxis.
Kaya Z; Gursel T; Kocak U; Aral YZ; Kalkanci A; Albayrak M
Pediatr Blood Cancer; 2009 Apr; 52(4):470-5. PubMed ID: 19058205
[TBL] [Abstract][Full Text] [Related]
51. Assessing the impact of prophylactic anidulafungin during remission induction of acute myeloid leukemia - A propensity-score matching analysis.
Silva WFD; Mendes FR; Melo RDCB; Velloso EDRP; Rocha V; Rego EM
J Mycol Med; 2023 Nov; 33(4):101434. PubMed ID: 37683564
[TBL] [Abstract][Full Text] [Related]
52. Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort.
Vehreschild JJ; Rüping MJ; Wisplinghoff H; Farowski F; Steinbach A; Sims R; Stollorz A; Kreuzer KA; Hallek M; Bangard C; Cornely OA
J Antimicrob Chemother; 2010 Jul; 65(7):1466-71. PubMed ID: 20410061
[TBL] [Abstract][Full Text] [Related]
53. Isavuconazole as Primary Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-label, Prospective, Phase 2 Study.
Bose P; McCue D; Wurster S; Wiederhold NP; Konopleva M; Kadia TM; Borthakur G; Ravandi F; Masarova L; Takahashi K; Estrov Z; Yilmaz M; Daver N; Pemmaraju N; Naqvi K; Rausch CR; Marx KR; Qiao W; Huang X; Bivins CA; Pierce SA; Kantarjian HM; Kontoyiannis DP
Clin Infect Dis; 2021 May; 72(10):1755-1763. PubMed ID: 32236406
[TBL] [Abstract][Full Text] [Related]
54. Antifungal prophylaxis during 7 + 3 induction chemotherapy for acute myeloid leukemia is associated with improved survival, in a setting with low incidence of invasive mold infections.
Hsu A; Matera R; Vieira K; Reagan JL; Farmakiotis D
Support Care Cancer; 2021 Feb; 29(2):707-712. PubMed ID: 32435969
[TBL] [Abstract][Full Text] [Related]
55. Economic evaluation of posaconazole vs. standard azole prophylaxis in high risk neutropenic patients in the Netherlands.
Stam WB; O'Sullivan AK; Rijnders B; Lugtenburg E; Span LF; Janssen JJ; Jansen JP
Eur J Haematol; 2008 Dec; 81(6):467-74. PubMed ID: 18754857
[TBL] [Abstract][Full Text] [Related]
56. Incidence of invasive fungal infection in acute lymphoblastic and acute myelogenous leukemia in the era of antimold prophylaxis.
Oh SM; Byun JM; Chang E; Kang CK; Shin DY; Koh Y; Hong J; Kim TS; Choe PG; Park WB; Kim NJ; Yoon SS; Kim I; Oh MD
Sci Rep; 2021 Nov; 11(1):22160. PubMed ID: 34773060
[TBL] [Abstract][Full Text] [Related]
57. Pharmacoeconomic evaluation of fluconazole, posaconazole and voriconazole for antifungal prophylaxis in patients with acute myeloid leukaemia undergoing first consolidation chemotherapy.
Heng SC; Slavin MA; Al-Badriyeh D; Kirsa S; Seymour JF; Grigg A; Thursky K; Bajel A; Nation RL; Kong DC
J Antimicrob Chemother; 2013 Jul; 68(7):1669-78. PubMed ID: 23485723
[TBL] [Abstract][Full Text] [Related]
58. Posaconazole prophylaxis during front-line chemotherapy of acute myeloid leukemia: a single-center, real-life experience.
Girmenia C; Frustaci AM; Gentile G; Minotti C; Cartoni C; Capria S; Trisolini SM; Matturro A; Loglisci G; Latagliata R; Breccia M; Meloni G; Alimena G; Foà R; Micozzi A
Haematologica; 2012 Apr; 97(4):560-7. PubMed ID: 22102706
[TBL] [Abstract][Full Text] [Related]
59. Systemic antifungal treatment after posaconazole prophylaxis: results from the SEIFEM 2010-C survey.
Pagano L; Verga L; Busca A; Martino B; Mitra ME; Fanci R; Ballanti S; Picardi M; Castagnola C; Cattaneo C; Nadali G; Nosari A; Candoni A; Caira M; Salutari P; Lessi F; Aversa F; Tumbarello M
J Antimicrob Chemother; 2014 Nov; 69(11):3142-7. PubMed ID: 24948702
[TBL] [Abstract][Full Text] [Related]
60. The Outcome of Antifungal Prophylaxis with Posaconazole in Patients with Acute Myeloid Leukemia: A Single-Center Study.
Özkocaman V; Özkalemkaş F; Seyhan S; Ener B; Ursavaş A; Ersal T; Kazak E; Demirdöğen E; Mıstık R; Akalın H
Turk J Haematol; 2018 Nov; 35(4):277-282. PubMed ID: 30047484
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
